Dan Sinai

EpiSign™ is the first-ever clinically validated test that analyzes genomic DNA methylation using cutting-edge artificial intelligence technologies to diagnose patients with rare diseases. EpiSign™ uses machine learning-based algorithms to discover and identify DNA methylation patterns, or episignatures, associated with specific rare diseases including genetic and environmental exposure disorders. These episignatures are stored in the EpiSign™ Knowledge Database, the world’s largest epigenetic database for rare diseases.